Expression of breast cancer anti-estrogen resistance 1 in relation to vascular endothelial growth factor, p53, and prognosis in esophageal squamous cell cancer
Expression of breast cancer anti-estrogen resistance 1 in relation to vascular endothelial growth factor, p53, and prognosis in esophageal squamous cell cancer
复制标题
乳腺癌抗雌激素抵抗1的表达与血管内皮生长因子、p53及食管鳞状细胞癌预后的关系
DOI：
10.1111/j.1442-2050.2012.01376.x
复制
发表时间：
2013-07-01
影响因子：
2.6
通讯作者：
Jiang, Y-G.
中科院分区：
文献类型：
--
作者：
Huang, W.;Deng, B.;Jiang, Y-G.
本研究的目的是阐明乳腺癌抗雌激素抵抗1 （BCAR1）表达在食管鳞状细胞癌（ESCC）中与血管内皮生长因子（VEGF）、p53和增殖的关系。应用组织芯片技术和免疫组化技术检测106例ESCC及邻近正常组织中BCAR1、VEGF、p53及ki-67增殖指数的表达。其中40例同时进行Western blot检测。Western blot和免疫组化结果显示，BCAR1在ESCC中的表达明显高于邻近正常组织（P < 0.001）。BCAR1表达与肿瘤分化程度显著相关，低分化肿瘤中BCAR1表达较高（P < 0.001）。BCAR1表达与VEGF、p53表达水平呈显著正相关（r= 0.541, P < 0.001; r= 0.374, P < 0.001），与增殖指数无显著正相关（r= 0.44， P= 0.066）。此外，VEGF与p53之间也存在显著相关性（r= 0.321； P= 0.001）。Kaplan-Meier生存分析显示，BCAR1高表达患者的生存时间明显短于BCAR1低表达患者（中位生存期40个月vs 27个月，P= 0.09）。多因素分析也显示BCAR1表达水平（风险比2.250，P= 0.015）是一个显著且独立的预后指标。BCAR1的高表达与ESCC中VEGF和p53表达水平升高以及预后不良相关。因此，BCAR1可能是预测ESCC预后的潜在候选者和新的治疗靶点。
The purpose of this study was to clarify the role of breast cancer anti-estrogen resistance 1 (BCAR1) expression in relation to vascular endothelial growth factor (VEGF), p53, and proliferation in esophageal squamous cell cancer (ESCC). Expression of BCAR1, VEGF, p53, and the ki-67 proliferative index were examined by tissue microarray and immunohistochemistry in 106 specimens with ESCC and matched adjacent normal tissues. Among them, 40 cases were simultaneously examined by Western blot. Both Western blot and immunohistochemistry showed that BCAR1 expression was substantially higher in ESCC than in adjacent normal tissues (P < 0.001). BCAR1 expression was significantly connected with degree of tumor differentiation, with poorly differentiated tumors showing higher BCAR1 expression (P < 0.001). BCAR1 expression was significantly and positively correlated with VEGF and p53 expression levels (r= 0.541, P < 0.001; r= 0.374; P < 0.001) but not proliferative index (r= 0.44; P= 0.066). Additionally, a significant relationship was also observed between VEGF and p53 (r= 0.321; P= 0.001). Kaplan-Meier survival analysis revealed that patients with high BCAR1 expression had significantly shorter survival times than those with low BCAR1 expression levels (median survival 40 months vs. 27 months, P= 0.09). Multivariate analysis also revealed that levels of BCAR1 expression (hazard ratio 2.250, P= 0.015) was a significant and independent prognostic indicator. High expression of BCAR1 is associated with elevated VEGF and p53 expression levels, as well as poor prognosis in ESCC. Therefore, BCAR1 may be a potential candidate for predicting prognosis and a new therapy target for ESCC.